GURUFOCUS.COM » STOCK LIST » Technology » Software » Enfusion Inc (NYSE:ENFN) » Definitions » Intrinsic Value: Projected FCF

Enfusion (Enfusion) Intrinsic Value: Projected FCF : $0.00 (As of Jun. 04, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Enfusion Intrinsic Value: Projected FCF?

Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company. The details of how we calculate the intrinsic value of stocks are described in detail here.

As of today (2024-06-04), Enfusion's Intrinsic Value: Projected FCF is $0.00. The stock price of Enfusion is $8.95. Therefore, Enfusion's Price-to-Intrinsic-Value-Projected-FCF of today is 0.0.

The historical rank and industry rank for Enfusion's Intrinsic Value: Projected FCF or its related term are showing as below:

ENFN's Price-to-Projected-FCF is not ranked *
in the Software industry.
Industry Median: 1.61
* Ranked among companies with meaningful Price-to-Projected-FCF only.

Enfusion Intrinsic Value: Projected FCF Historical Data

The historical data trend for Enfusion's Intrinsic Value: Projected FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Enfusion Intrinsic Value: Projected FCF Chart

Enfusion Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Intrinsic Value: Projected FCF
- - - - -

Enfusion Quarterly Data
Dec19 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Intrinsic Value: Projected FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Enfusion's Intrinsic Value: Projected FCF

For the Software - Application subindustry, Enfusion's Price-to-Projected-FCF, along with its competitors' market caps and Price-to-Projected-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Enfusion's Price-to-Projected-FCF Distribution in the Software Industry

For the Software industry and Technology sector, Enfusion's Price-to-Projected-FCF distribution charts can be found below:

* The bar in red indicates where Enfusion's Price-to-Projected-FCF falls into.



Enfusion Intrinsic Value: Projected FCF Calculation

Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company.

The details of how we calculate the intrinsic value of stocks are described in detail here.

This method smooths out the free cash flow over the past 6-7 years, multiplies the results by a growth multiple, and adds a portion of Total Stockholders Equity.

Intrinsic Value: Projected FCF = ( Growth Multiple * Free Cash Flow (6 year avg) + 0.8 * Total Stockholders Equity (most recent) ) / Shares Outstanding (Diluted Average)

In the case of negative Total Stockholders Equity, the following formula is used (see Explanation section below for the reason):

Intrinsic Value: Projected FCF = ( Growth Multiple * Free Cash Flow (6 year avg) + Total Stockholders Equity (most recent) / 0.8 ) / Shares Outstanding (Diluted Average)



Enfusion  (NYSE:ENFN) Intrinsic Value: Projected FCF Explanation

The growth multiple is capped between 8.35 and 17.74.

Total Stockholders Equity weighting is more art than science and it should always be revisited in more detail when researching a company. Weightings from 0% to 100% to more than 100% are possible. 80% was chosen as a happy median after taking the above ideas into consideration.

Enfusion's Price-to-Intrinsic-Value-Projected-FCF for today is calculated as

Price-to-Intrinsic-Value-Projected-FCF=Share Price/Intrinsic Value: Projected FCF
=8.95/
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Enfusion Intrinsic Value: Projected FCF Related Terms

Thank you for viewing the detailed overview of Enfusion's Intrinsic Value: Projected FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Enfusion (Enfusion) Business Description

Industry
Traded in Other Exchanges
N/A
Address
125 South Clark Street, Suite 750, Chicago, IL, USA, 60603
Enfusion Inc is a software-as-a-service (SaaS) provider focused on transforming the investment management industry. Its solutions are designed to eliminate technology and information barriers, empowering investment managers to make and execute better-informed investment decisions in real-time. It simplifies investment and operational workflows by unifying mission-critical systems and coalescing data into a single dataset resulting in a single source of truth.
Executives
Deirdre Somers director C/O ENFUSION, INC., 125 SOUTH CLARK STREET, SUITE 750, CHICAGO IL 60603
Bradley Herring officer: Chief Financial Officer C/O SHIFT4 PAYMENTS, INC., 2202 N. IRVING STREET, ALLENTOWN PA 16109
Oleg Movchan director, 10 percent owner C/O ENFUSION INC., 125 SOUTH CLARK ST. STE 750, CHICAGO IL 60603
Bronwen Bastone officer: Chief People Officer C/O ENFUSION, INC., 125 SOUTH CLARK STREET SUITE 750, CHICAGO IL 60603
Stephen Malherbe 10 percent owner C/O ENFUSION, INC., 125 SOUTH CLARK STREET, SUITE 750, CHICAGO IL 60603
Dan Groman officer: Chief Technology Officer C/O ENFUSION INC., 125 SOUTH CLARK STREET STE. 750, CHICAGO IL 60603
Tarek Hammoud 10 percent owner C/O ENFUSION INC., 125 SOUTH CLARK ST. STE. 750, CHICAGO IL 60603
Ftv Investment Holdings, L.p. 10 percent owner 601 CALIFORNIA STREET, FLOOR 19, SAN FRANCISCO CA 94108
Michael Spellacy director 399 PARK AVENUE, NEW YORK NY 10022
Quiet Light Securities, Llc 10 percent owner 70 WEST MADISON, SUITE 1675, CHICAGO IL 60602
Steven M. Bachert officer: Chief Revenue Officer C/O ENFUSION INC., 125 SOUTH CLARK ST., STE 750, CHIGAGO IL 60603
Lra Ventures, Llc 10 percent owner C/O ENFUSION, INC., 125 SOUTH CLARK STREET, SUITE 750, CHICAGO IL 60603
Hillhouse Investment Management, Ltd. 10 percent owner OFFICE #122, WINDWARD 3 BUILDING, REGATTA OFFICE PARK, WEST BAY ROAD, GRAND CAYMAN E9 KY1-9006
Roy Luo director 394 PACIFIC AVENUE, 2ND FLOOR, SAN FRANCISCO CA 94111
Iconiq Strategic Partners V-b, L.p. 10 percent owner 394 PACIFIC AVENUE, SECOND FLOOR, SAN FRANCISCO CA 94111

Enfusion (Enfusion) Headlines